- $766.88m
- $537.68m
- $0.58m
- 37
- 21
- 78
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.3 | ||
| Price to Tang. Book | 3.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.44% | ||
| Return on Equity | -42.23% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.62 | 7.8 | 0.58 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. It is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). It is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.
Directors
- Tadataka Yamada NEC (76)
- Adam Simpson PRE (46)
- Thomas Russo CFO (50)
- Charles Richardson SVP (69)
- Douglas Holtzman CSO (57)
- Elizabeth Bekiroglu GCN
- Cassia Cearley OTH (39)
- Niranjan Kanesa-Thasan OTH (61)
- Elisha Gould IND (64)
- Peter Kolchinsky IND (45)
- Heidi Kunz IND (67)
- Mark McDade IND (66)
- John Shiver IND
- Ann Veneman IND (72)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- November 1st, 2017
- Public Since
- July 29th, 2021
- No. of Shareholders
- 33
- No. of Employees
- 60
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 50,090,341
- Address
- 1930 Boren Ave., Suite 1000, SEATTLE, 98101
- Web
- https://icosavax.com/
- Phone
- +1 2067370085
- Auditors
- Ernst & Young LLP
Upcoming Events for ICVX
Similar to ICVX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:11 UTC, shares in Icosavax are trading at $15.31. This share price information is delayed by 15 minutes.
Shares in Icosavax last closed at $15.31 and the price had moved by +72.6% over the past 365 days. In terms of relative price strength the Icosavax share price has outperformed the S&P500 Index by +40.66% over the past year.
The overall consensus recommendation for Icosavax is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIcosavax does not currently pay a dividend.
Icosavax does not currently pay a dividend.
Icosavax does not currently pay a dividend.
To buy shares in Icosavax you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $15.31, shares in Icosavax had a market capitalisation of $766.88m.
Here are the trading details for Icosavax:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ICVX
Based on an overall assessment of its quality, value and momentum Icosavax is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Icosavax is $18.50. That is 20.84% above the last closing price of $15.31.
Analysts covering Icosavax currently have a consensus Earnings Per Share (EPS) forecast of -$2.14 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Icosavax. Over the past six months, its share price has outperformed the S&P500 Index by +82.59%.
As of the last closing price of $15.31, shares in Icosavax were trading +52.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Icosavax PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Icosavax's management team is headed by:
- Tadataka Yamada - NEC
- Adam Simpson - PRE
- Thomas Russo - CFO
- Charles Richardson - SVP
- Douglas Holtzman - CSO
- Elizabeth Bekiroglu - GCN
- Cassia Cearley - OTH
- Niranjan Kanesa-Thasan - OTH
- Elisha Gould - IND
- Peter Kolchinsky - IND
- Heidi Kunz - IND
- Mark McDade - IND
- John Shiver - IND
- Ann Veneman - IND